| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2025 | ESPR Esperion Therapeutics, Inc. | Halladay Benjamin | Chief Financial Officer | Sell | 3,535 | $1.48 | $5,242.41 | -0.7% | -25.9% | +58.9% | |
| Mar 18, 2025 | NIKA Nika Pharmaceuticals, Inc | Savov Dimitar Slavchev | CEO, CFO, President | Sell | 2,000,000 | $0.25 | $500,000.00 | -0.4% | - | - | |
| Mar 18, 2025 | ESPR Esperion Therapeutics, Inc. | Koenig Sheldon L.63 | President And CEO | Sell | 13,047 | $1.50 | $19,622.69 | -0.8% | -25.9% | +58.9% | |
| Mar 18, 2025 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 3,236 | $34.31 | $111,027.16 | -1.8% | +89.8% | -26.5% | |
| Mar 18, 2025 | HIMS Hims & Hers Health, Inc. | Carroll Patrick Harrison52 | Chief Medical Officer | Sell | 23,287 | $34.31 | $798,976.97 | -10.0% | +89.8% | -26.5% | |
| Mar 18, 2025 | HIMS Hims & Hers Health, Inc. | Becklund Irene | Pao | Sell | 8,277 | $34.31 | $283,983.87 | -44.8% | +89.8% | -26.5% | |
| Mar 18, 2025 | HIMS Hims & Hers Health, Inc. | Dudum Andrew47 | Chief Executive Officer | Sell | 254,421 | $33.87 | $8,618,493.25 | -11.0% | +89.8% | -26.5% | |
| Mar 17, 2025 | LNTH Lantheus Holdings, Inc. | Marshall Robert J. Jr.54 | CFO And Treasurer | Sell | 10,000 | $100.52 | $1,005,200.00 | -8.1% | -24.3% | -21.7% | |
| Mar 17, 2025 | VREOF Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 10% Owner | Buy | 123,022 | $0.38 | $46,800.43 | +28.7% | - | - | |
| Mar 14, 2025 | ETST Earth Science Tech, Inc. | Sanchez Yovan Arturo | Director | Buy | 100,000 | $0.12 | $12,000.00 | +6.6% | - | - | |
| Mar 14, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Patel Tushar Bhikhubhai | - | Sell | 5,000,000 | $8.35 | $41,750,000.00 | -9.3% | -9.0% | +35.2% | |
| Mar 14, 2025 | COLL Collegium Pharmaceutical, Inc | Tupper Colleen45 | EVP &Chief Financial Officer | Sell | 977 | $30.00 | $29,313.32 | -0.6% | +0.5% | +17.1% | |
| Mar 14, 2025 | COLL Collegium Pharmaceutical, Inc | Dreyer Scott54 | EVP &Chief Commercial Officer | Sell | 2,255 | $30.00 | $67,661.05 | -1.8% | +0.5% | +17.1% | |
| Mar 13, 2025 | ANIP Ani Pharmaceuticals Inc | Cook Meredith50 | Sr. VP, General Counsel &Sec. | Sell | 400 | $63.33 | $25,332.00 | -0.5% | +2.2% | +14.7% | |
| Mar 13, 2025 | VRNO Verano Holdings Corp. | Summerer Brett Andrew | Chief Financial Officer | Sell | 28,093 | $0.62 | $17,369.90 | -19.1% | - | - | |
| Mar 13, 2025 | LLY Eli Lilly & Co | Zakrowski Donald A | SVP, Finance, &CAO | Sell | 1,000 | $818.24 | $818,240.00 | -14.6% | +0.9% | +22.9% | |
| Mar 13, 2025 | VREOF Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 10% Owner | Buy | 32,222,500 | $0.62 | $20,084,465.95 | +41.0% | - | - | |
| Mar 13, 2025 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | Director | Sell | 3 | $93.84 | $281.52 | - | -18.7% | -19.9% | |
| Mar 12, 2025 | EOLS Evolus, Inc. | Parschauer Karah Herdman77 | Director | Sell | 12,888 | $12.99 | $167,465.38 | -28.6% | -26.5% | -63.4% | |
| Mar 12, 2025 | EBS Emergent Biosolutions Inc. | Fowler Neal Franklin | Director | Sell | 35,000 | $5.83 | $204,050.00 | -25.7% | +9.8% | +32.2% | |
| Mar 12, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | Chief Financial Officer | Sell | 36,372 | $22.25 | $809,277.00 | -61.3% | +32.3% | +104.8% | |
| Mar 12, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Megna Michael R | Chief Accounting Officer | Sell | 9,051 | $22.45 | $203,194.95 | -25.4% | +32.3% | +104.8% | |
| Mar 12, 2025 | EBS Emergent Biosolutions Inc. | Zoon Kathryn C62 | Director | Sell | 10,000 | $5.73 | $57,300.00 | -18.4% | +9.8% | +32.2% | |
| Mar 11, 2025 | DERM Journey Medical Corp | Maraoui Claude | President &CEO | Sell | 49,271 | $5.01 | $246,847.71 | -2.4% | +39.0% | +58.8% | |
| Mar 11, 2025 | COLL Collegium Pharmaceutical, Inc | Tupper Colleen45 | EVP &Chief Financial Officer | Sell | 10,445 | $30.01 | $313,412.67 | -5.9% | +1.5% | +18.8% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.